PRVL - Passage Bio Files Initial Plan For IPO
Quick Take
Passage Bio (PASG) has filed to raise $125 million in an IPO of its common stock, according to an S-1 registration statement.
The firm is developing genetic treatments for monogenic (single gene) central nervous system [CNS] health conditions.
PASG is at pre-clinical stage so is an ultra-high-risk firm potentially more suited to institutional investors with a long hold time frame.
I’ll provide a final opinion when we learn more IPO details from management.
Company & Technology
Philadelphia-based Passage was founded to advance genetic treatments involving a single gene for rare